EGFR and cancer: Although kinase inhibitory activity (ESI Fig. S2†) or apoptosis (ESI Fig. S1†) were not observed for 4f, the data do suggest that a future in vivo bioavailable derivative of 4f could be used as a combination with osimertinib to target cancers with mutated/amplified EGFR.